tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Repligen’s Strong Q2 Performance and Growth Prospects Justify Buy Rating

Repligen’s Strong Q2 Performance and Growth Prospects Justify Buy Rating

William Blair analyst Matt Larew has maintained their bullish stance on RGEN stock, giving a Buy rating today.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Matt Larew has given his Buy rating due to a combination of factors, including Repligen’s impressive second-quarter performance and its strong growth outlook. The company exceeded revenue expectations, reporting $182.4 million compared to the anticipated $177.1 million, and also surpassed consensus estimates. This strong financial performance was driven by a 17% non-COVID organic growth, which was higher than the estimated 14%.
Additionally, Repligen raised its guidance for the full year, projecting revenues between $715 million and $735 million, with non-COVID organic growth expectations increased to 12.5% to 15.5%. The company’s robust order momentum, with orders rising both sequentially and year-over-year, further supports the positive outlook. These factors, combined with the company’s position in a bioprocessing market that is returning to normalized levels, underpin the Buy rating as Repligen demonstrates a best-in-class growth profile poised for continued success.

According to TipRanks, Larew is an analyst with an average return of -3.6% and a 49.09% success rate. Larew covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, 908 Devices, and AptarGroup.

In another report released today, Craig-Hallum also maintained a Buy rating on the stock with a $0.00 price target.

Disclaimer & DisclosureReport an Issue

1